Plain-English translation of NCT05939414 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new treatment called lutetium (177Lu) vipivotide tetraxetan () to see if it can help men with early-stage advanced prostate cancer live longer without needing hormone therapy or experiencing cancer growth. All participants first receive targeted radiation to destroy visible cancer spots, then half receive four doses of this new medication over several months, while the other half are monitored without additional treatment. The researchers want to learn whether this medication helps delay cancer from coming back or spreading.
When prostate cancer spreads to just a few spots in the body, it creates a window of opportunity to try new treatments before starting hormone therapy, which can have significant side effects. This trial exists to see if this medication can take advantage of that window and help men stay healthier for longer.
You likely qualify if…
You likely don't qualify if…
Over about 6.5 years, you will first receive targeted radiation therapy to all visible cancer spots, which takes about 3 weeks. If randomly assigned to the treatment group, you will then receive four doses of the new medication spaced 6 weeks apart. If assigned to the observation group, you will simply be monitored after radiation. Both groups will have frequent check-in visits during the first few months, then less frequent visits every 16 weeks, with imaging scans to track how your cancer is responding.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United States